Great news, finally.
I was wondering about what numbers we could be seeing with both the Eisai partnership and the ERT partnership.
I understand that there is huge potential here, but it's not as if the company has been profitable, right? How should one think about it?
If we divide those $45 Million from Eisai by 10 years, we're talking about $4,5 Million per year. Let's say that it's all profit and slap a 20x multiple on it. That would mean a AUD$126 Million marketcap. The current marketcap is $206 Million, so Mr Market is ascribing a AUD$80 Million value for the Clinical Trials and Research segments.
Is this too low? The administration costs have been consistently higher (or just a bit lower) than the operating profit from the Clinical Trials segment, so...
If Aducanumab doesn't go forward, should we expect a decline in Clinical Trials revenue?
Cheers
- Forums
- ASX - By Stock
- CGS
- Putting numbers on it
Putting numbers on it
-
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGS (ASX) to my watchlist
|
|||||
Last
92.5¢ |
Change
-0.015(1.60%) |
Mkt cap ! $157.9M |
Open | High | Low | Value | Volume |
92.5¢ | 95.0¢ | 91.5¢ | $157.5K | 170.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3377 | 92.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
93.5¢ | 246 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3377 | 0.925 |
2 | 4891 | 0.915 |
1 | 3800 | 0.910 |
1 | 75032 | 0.900 |
4 | 60261 | 0.890 |
Price($) | Vol. | No. |
---|---|---|
0.935 | 246 | 1 |
0.940 | 9200 | 3 |
0.945 | 3800 | 1 |
0.950 | 4018 | 2 |
0.975 | 43931 | 1 |
Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
Featured News
CGS (ASX) Chart |